Important Update on Testosterone Replacement Therapy (TRT)
An expert panel convened by the Food and Drug Administration (FDA) has recommended relaxing restrictions on testosterone replacement therapy (TRT), making it more accessible to millions of men. This decision follows new clinical trials that suggest TRT does not increase the risk of heart attack, stroke, or prostate cancer in appropriately selected males.
The panel's recommendations aim to expand access to TRT for a broader group of individuals, including those with age-related low testosterone levels. If adopted, these changes could help address the growing public health issue of testosterone deficiency in American men.
Current Uses and Limitations of TRT
TRT is currently approved only for low testosterone (hypogonadism) associated with specific medical causes, such as:
- testicular dysfunction
- pituitary disorders
- hypothalamic disease
However, the FDA's indications are not aligned with guidelines from professional organizations like the American Urological Association, which recommend considering testosterone therapy for males with confirmed low testosterone levels and clinical symptoms.
New Recommendations and Potential Changes
The expert panel recommended:
- expanding FDA-approved indications to include age-related low testosterone
- removing its Schedule III controlled substance designation
The panel also emphasized the importance of routine screening for low testosterone, similar to lipid panels and other commonly ordered blood tests. If implemented, these changes could make TRT more accessible and help address the growing health concerns associated with testosterone deficiency.
Learn more about hair transplant at Rubenhair clinic.
Get a Free Consultation
Consult with our specialists about FUE procedure, PRP therapy or hair transplant.
